Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
Contacts
Related Blogs
Capabilities
Suggested News & Insights
In House Hearing, DAAG Jenny Discusses FCA Enforcement Priorities Related to Grants, Faces Questioning on Using FCA to Target DiscriminationJune 29, 2026DOJ Reaches $507,144 Settlement with Defense Contractor, Signals Increased FCA Scrutiny of Cybersecurity Self-AssessmentsJune 23, 2026Challenging Executive Order on DEI, States Say It Gets FCA Materiality WrongJune 15, 2026Sidley Highly Ranked in Chambers USA 2026June 4, 2026DOJ’s Civil Rights Fraud Initiative Raises False Claims Act Risks for Healthcare and Life Sciences CompaniesJune 4, 2026DOJ Announces Accelerated Review of FCA Qui Tams Alleging Fraud Against State-Administered Benefits ProgramsMay 28, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory